VBL To Test Gene Therapy In Phase III After FDA Lifts Hold
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Israeli biotech will commence its Phase III recurrent glioblastoma trial in mid-2015, believes combination therapy with its VB-111 and Avastin can improve overall survival. As it starts its first Phase III trial, VBL also halted work on its lead anti-inflammatory product.
You may also be interested in...
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.
Patent Office Issues Proposed Rule For Rarely Successful Director Review Requests
The rulemaking is supposed to formalize the Patent Trial and Appeal Board process, which has been in an interim status since a Supreme Court decision, giving manufacturers more ability to request oversight of the decisions.